CEO to Discuss the Company’s Latest Advances in Spinal Cord Injury Treatment on December 18th
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds is scheduled to appear on WBAL-TV’s Sunday morning newscast on December 18th during their 8:00 AM (Eastern Time) newscast.
InVivo Therapeutics has pioneered a new treatment platform that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after a traumatic spinal cord injury. Reynolds will discuss the scaffold and how it is expected to work in humans, as well as results from InVivo’s largest non-human primate study.
“We expect that our technology will change the standard treatment for spinal cord injury. We’re currently under review at the FDA and we look forward to receiving approval from the FDA to begin human studies,” said Reynolds. “Our therapeutic approach confirms a clear paradigm in the treatment of spinal cord injuries, and we look forward to being on WBAL-TV.”
WBAL-TV is the NBC affiliate in Baltimore airing on channel 11, locally. The 11 News Sunday Morning show is a top-rated weekend morning show in the Baltimore market.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
KEYWORDS: United States North America Maryland Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Medical Devices Other Health FDA General Health